Basel Medical Group Subsidiary Awarded S$375 Million Contract to Supply Healthcare Products; Group to Enhance AI-Powered Healthcare Supply Chain Capabilities
May 20 2025 - 9:20AM
Basel Medical Group Ltd (Nasdaq: BMGL or the “Company”), today
announced that its subsidiary has been awarded a significant
contract worth S$375 million by Pancare Technology International
(HK) Limited to supply essential healthcare products in
Asia-Pacific over the next five years until October 31, 2029. This
milestone underscores the Company’s commitment to delivering
high-quality medical solutions and strengthening its global
presence in the healthcare sector.
As part of the Company’s strategic vision, the
Company will be accelerating the integration of AI-powered
technologies into its healthcare supply chain operations. This
initiative aims to enhance efficiency, optimize logistics, and to
ensure the timely delivery of critical medical products to
healthcare providers across Asia-Pacific and beyond.
Key Highlights:
- S$375M Contract Award: The
subsidiary will supply a range of healthcare products, supporting
Asia-Pacific’s medical infrastructure over the next five
years.
- AI-Driven Supply Chain: The Company
will leverage artificial intelligence to improve demand
forecasting, inventory management, and distribution accuracy.
- Commitment to Innovation: The
Company continues to invest in cutting-edge technology to enhance
healthcare delivery and operational excellence.
“We are honored to secure this contract, which
reflects the trust placed in our capabilities,” said Dr Darren
Chhoa, CEO of the Company. “Our focus on AI-powered supply chain
solutions will ensure reliable, efficient, and scalable healthcare
product distribution, benefiting patients and providers alike.”
This achievement aligns the Company’s mission to
transform global healthcare through innovation, technology, and
sustainable practices.
About Basel Medical Group
Ltd
Basel Medical is a Singapore-based provider of
orthopedic and trauma services, sports medicine and surgery,
orthopedic procedures, as well as neurosurgical treatments. Our
operations are based in Singapore, with our clinics being at 6
Napier Road, Unit #02-10/11 and Unit #03-07, Gleneagles Medical
Centre. Over the last 20 years, our group has forged strong and
lasting relationships with a large base of corporations, in
particular those in the construction, marine and oil & gas
industries, which underpin our robust business model. As an
orthopedic service provider in Singapore with a track record of
over 20 years, we are well-positioned to ride the wave of growth
opportunities in the private healthcare industry in Singapore and
across Southeast Asia driven by ageing populations, rising income
levels, increasing private insurance coverage, government effort
and expenditure on healthcare, growing sports participation rate
and Singapore’s position as a premium destination for healthcare
services in Asia. Our management and medical practitioner team
comprises a roster of orthopedic and neurosurgery specialists,
corporate finance and healthcare partnership specialists. Basel
Medical Group Ltd serves as the holding company of our group and we
conduct our operations through our operating subsidiaries based in
Singapore. For more information, please visit the Company’s
website: www.baselmedical.com.
Forward-Looking Statements
Certain statements in this announcement are
forward-looking statements, which involve known and unknown risks
and uncertainties and are based on the Company’s current
expectations and projections about future events that may affect
its financial condition, results of operations, business strategy
and financial needs. Investors can find many (but not all) of these
statements by the use of words such as “aim”, “anticipate”,
“believe”, “estimate”, “expect”, “going forward”, “intend”, “may”,
“plan”, “potential”, “predict”, “propose”, “seek”, “should”,
“will”, “would” or other similar expressions in this press release.
The Company undertakes no obligation to update or revise publicly
any forward-looking statements to reflect subsequent occurring
events or circumstances, or changes in its expectations, except as
may be required by law. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual
results may differ materially from the anticipated results and
encourages investors to review other factors that may affect its
future results in the Company’s filings with the SEC.
Media Contact: Basel Medical
Group Ltd +65 6291
9188contact@baselmedical.comwww.baselmedical.com
Basel Medical (NASDAQ:BMGL)
Historical Stock Chart
From Jun 2025 to Jul 2025
Basel Medical (NASDAQ:BMGL)
Historical Stock Chart
From Jul 2024 to Jul 2025